J Alzheimer's Dis 91, 449461
Said method comprises with the higher dosage of selecting of dosage regimen that the invasive tumor obstacle uses or select that is compared to uses coenzyme Q10 to the people, thereby treats or prevent Non-Invasive tumor obstacle.In certain embodiments, said Non-Invasive tumor obstacle comprises non-metastatic breast carcinoma, androgen dependent prostate cancer, small cell lung cancer, acute lymphoblastic leukemia.In certain embodiments, intermediate product comprises: the biosynthetic molecule of benzoquinone or at least a promotion benzoquinone ring, and with the molecule that is connected of unitary synthetic and/or isoprenoid unit to the benzoquinone ring of (b) at least a promotion isoprenoid.In other embodiments, the biosynthetic molecule of said at least a promotion benzoquinone ring comprises: L-phenylalanine, DL-phenylalanine, D-phenylalanine, L-tyrosine, DL-tyrosine, D-tyrosine, 4-hydroxyl-propiophenone acid esters, 3 methoxy 4 hydroxymandelic acid ester (vanillylmandelic acid (VMA) ester or VMA), vanillic acid, pyridoxin or pantothenylol.In other embodiments, the molecule of the connection of unitary synthetic and/or isoprenoid unit to the benzoquinone ring of said at least a promotion isoprenoid comprises: phenylacetate, 4-hydroxy-benzoic acid ester, mevalonic acid, acetoglycocoll, acetyl-CoA or farnesyl-.In other embodiments, said intermediate product comprises: (a) one or more of L-phenylalanine, L-tyrosine and 4-HPPA
nal , Cansz D, Beler M, Sezer Z, Gzel E, Emekli-Alturfan E
doi:10.1097/MBC.0b013e32835bdc8f Yang L, Qian Z, Yang Y, et al
